Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Arbutus Biopharma Corporation is a biotechnology business based in the US. Arbutus Biopharma Corporation shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma Corporation employs 78 staff and has a trailing 12-month revenue of around USD$6.1 million.
|Latest market close||USD$3|
|52-week range||USD$0.88 - USD$6.48|
|50-day moving average||USD$3.8635|
|200-day moving average||USD$3.107|
|Wall St. target price||USD$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.79|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||-25.74%|
|1 month (2020-12-18)||-31.03%|
|3 months (2020-10-20)||4.17%|
|6 months (2020-07-20)||1.01%|
|1 year (2020-01-17)||-2.28%|
|2 years (2019-01-18)||-18.70%|
|3 years (2018-01-19)||5.2|
|5 years (2016-01-20)||3.51|
|Revenue TTM||USD$6.1 million|
|Gross profit TTM||USD$-51,590,000|
|Return on assets TTM||-25.05%|
|Return on equity TTM||-78.86%|
|Market capitalisation||USD$328.6 million|
TTM: trailing 12 months
There are currently 2.9 million Arbutus Biopharma Corporation shares held short by investors – that's known as Arbutus Biopharma Corporation's "short interest". This figure is 37.8% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Arbutus Biopharma Corporation shares can be evaluated.
Arbutus Biopharma Corporation's "short interest ratio" (SIR) is the quantity of Arbutus Biopharma Corporation shares currently shorted divided by the average quantity of Arbutus Biopharma Corporation shares traded daily (recently around 4.9 million). Arbutus Biopharma Corporation's SIR currently stands at 0.6. In other words for every 100,000 Arbutus Biopharma Corporation shares traded daily on the market, roughly 600 shares are currently held short.
However Arbutus Biopharma Corporation's short interest can also be evaluated against the total number of Arbutus Biopharma Corporation shares, or, against the total number of tradable Arbutus Biopharma Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arbutus Biopharma Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Arbutus Biopharma Corporation shares in existence, roughly 30 shares are currently held short) or 0.0438% of the tradable shares (for every 100,000 tradable Arbutus Biopharma Corporation shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arbutus Biopharma Corporation.
Find out more about how you can short Arbutus Biopharma Corporation stock.
We're not expecting Arbutus Biopharma Corporation to pay a dividend over the next 12 months.
Arbutus Biopharma Corporation's shares were split on a 1:5 basis on 4 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma Corporation shares which in turn could have impacted Arbutus Biopharma Corporation's share price.
Over the last 12 months, Arbutus Biopharma Corporation's shares have ranged in value from as little as $0.88 up to $6.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 3.2724. This would suggest that Arbutus Biopharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.